-
Dec 2019
A composite immune signature parallels disease progression across T1D subjects.
JCI InsightSpeake C, Skinner SO, Berel D, Whalen E, Dufort MJ, Young WC, Odegard JM, Pesenacker AM, Gorus FK, James EA, Levings MK, Linsley PS, Akirav EM, Pugliese A, Hessner MJ, Nepom GT, Gottardo R, Long SA -
Aug 2019
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
N Engl J MedHerold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Aug 2019
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D.
Curr Opin Endocrinol Diabetes ObesLinsley PS, Long SA -
Jul 2019
Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy individuals.
Sci ImmunolKlicznik MM, Morawski PA, Höllbacher B, Varkhande SR, Motley SJ, Kuri-Cervantes L, Goodwin E, Rosenblum MD, Long SA, Brachtl G, Duhen T, Betts MR, Campbell DJ, Gratz IK -
Jul 2019
Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.
DiabetesAhmed S, Cerosaletti K, James EA, Long SA, Mannering SI, Speake C, Nakayama M, Tree T, Roep BO, Herold KC, Brusko TM -
Jun 2019
Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.
DiabetesHabib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum CJ, Buckner JH, Type 1 Diabetes TrialNet Study Group. -
Jun 2019
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
DiabetesHaller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group. -
Apr 2019
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
DiabetologiaPerdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC, Immune Tolerance Network. -
Feb 2019
B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
JCI InsightLinsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ -
Aug 2018
Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Clin ImmunolLord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH -
Aug 2018
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Pediatr DiabetesWeir GC, Ehlers MR, Harris KM, Kanaparthi S, Long SA, Phippard D, Weiner LJ, Jepson B, McNamara JG, Koulmanda M, Strom TB, ITN RETAIN Study Team. -
May 2018
Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome.
JCI InsightMorrell ED, Wiedeman A, Long SA, Gharib SA, West TE, Skerrett SJ, Wurfel MM, Mikacenic C -
Sep 2017
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Cell ImmunolLong SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM -
Aug 2017
Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.
Clin ImmunolSchwedhelm K, Thorpe J, Murray SA, Gavin M, Speake C, Greenbaum C, Cerosaletti K, Buckner J, Long SA -
Nov 2016
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
Sci ImmunolLong SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS
